POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
<p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p>&...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Столичная издательская компания,
2016-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p><p><strong>Material and methods.</strong> 45 women with PO, HT (1-2 stage) and medium/high cardiovascular risk were included in the study. 23 patients of the main group received strontium ranelate 2 g once daily additionally to antihypertensive and calcium replacement therapies. Before therapy and after 10 months MBD was evaluated by dual-energy x-ray absorbtiometry (DEXA) with usage of peripheral densitometer. Strontium ranelate effects on carotid intima-media thickness (duplex scanning) and morphofunctional cardiac indices (echocardiography) also were assessed.</p><p><strong>Results.</strong> Strontium ranelate therapy in patients with PO and HT leads to BMD rising and retardation of cardiovascular remodeling.</p><p><strong>Conclusion.</strong> Strontium ranelate is effective antiosteoporotic drug with positive influence on morphofunctional cardiac indices and carotid intima-media thickness. </p> |
|---|---|
| Item Description: | 1819-6446 2225-3653 10.1234/1819-6446-2009-2-18-21 |